CVS Health Corp vs Equinor ASA — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while Equinor ASA trades at $42.85 (market cap $100.03B). The key difference: CVS Health Corp and Equinor ASA are close in size by market cap, and Equinor ASA pays the higher dividend (3.75%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Equinor ASA for 59 Days on average.
| CVS | EQNR | |
|---|---|---|
Market Cap | $112.49B | $100.03B |
Volume | 8,467,392 | 4,457,638 |
Sector | Health | Energy |
52-Week High | $110.60 | $45.75 |
52-Week Low | $70.08 | $22.41 |
Typical Hold Time | 83 Days | 59 Days |
Enterprise Value | $174.83B | $108.72B |
Dividend Yield | 3.02% | 3.75% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Equinor (EQNR) trades at $42.93, down 0.19% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The stock presents compelling value with a P/E of 11.28 and EV/EBITDA of 2.35, well below industry averages. Recent developments include expansion in LNG operations and carbon capture projects, while maintaining strong operational cash flow of $20B. The company continues shareholder returns through dividends and buybacks.
EQNR offers significant upside potential with a consensus price target of $70.50 representing 64% upside, supported by improving earnings outlook and strategic LNG expansion. Key risks include volatile energy prices and execution challenges in new projects. Analyst sentiment is mixed with 30% buy ratings, but recent Zacks upgrades to Strong Buy highlight growing optimism about earnings recovery through 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →